secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celldex Therapeutics, Inc. (CLDX)
CIK:        0000744218
Form:       8-K
Filed at:   2021-07-14T23:59:59+00:00
Accession:  0001104659-21-092099
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celldex prices upsized $250M public offering at $42/share; net proceeds ~$234.8M
--------------------------------------------------------------------------------

- Celldex priced 5,952,381 shares at $42.00 per share in an upsized public offering for $250M gross proceeds.
- Expected net proceeds of ~$234.8M after underwriting discounts and estimated expenses.
- Proceeds to fund clinical development of CDX-0159 and other pipeline candidates, and bispecific antibody platform.
- Underwriters have 30-day option to purchase up to 892,857 additional shares at the same price.
- Offering expected to close July 16, 2021; joint book-runners: Jefferies, SVB Leerink, Guggenheim, Cantor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744218/000110465921092099/0001104659-21-092099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744218/000110465921092099/tm2121701d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-092099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer